These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14766884)

  • 1. Comparison of two microdilution methods for testing susceptibility of Candida spp. to voriconazole.
    Linares MJ; Charriel G; Solís F; Casal M
    J Clin Microbiol; 2004 Feb; 42(2):899-902. PubMed ID: 14766884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of voriconazole and other antifungal agents against clinical isolates of 138 Candida spp].
    Ricciardi AM; Ricciardi R; Danzi M; Mungiguerra M; Pisano L; Marino A
    Infez Med; 2009 Mar; 17(1):24-7. PubMed ID: 19359821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole.
    Pfaller MA; Espinel-Ingroff A; Jones RN
    J Clin Microbiol; 2004 Oct; 42(10):4577-80. PubMed ID: 15472311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods.
    Linares MJ; Charriel G; Solís F; Rodriguez F; Ibarra A; Casal M
    J Clin Microbiol; 2005 Jan; 43(1):250-3. PubMed ID: 15634979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001.
    Pfaller MA; Diekema DJ; Messer SA; Boyken L; Hollis RJ
    J Clin Microbiol; 2003 Apr; 41(4):1440-6. PubMed ID: 12682127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media.
    Pfaller MA; Messer SA; Houston A; Mills K; Bolmstrom A; Jones RN
    J Clin Microbiol; 2000 Oct; 38(10):3715-7. PubMed ID: 11015389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
    Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole and fluconazole susceptibility of Candida isolates.
    Pelletier R; Loranger L; Marcotte H; DE Carolis E
    J Med Microbiol; 2002 Jun; 51(6):479-483. PubMed ID: 12018654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods.
    Salgado-Parreño FJ; Alcoba-Flórez J; Arias A; Moragues MD; Quindós G; Pontón J; Arévalo MP
    Microb Drug Resist; 2006; 12(4):246-51. PubMed ID: 17227209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Ellis D; Tullio V; Rodloff A; Fu W; Ling TA;
    J Clin Microbiol; 2010 Apr; 48(4):1366-77. PubMed ID: 20164282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorimetric method for susceptibility testing of voriconazole and other triazoles against Candida species.
    Kauffman CA; Zarins LT
    Mycoses; 1999; 42(9-10):539-42. PubMed ID: 10592697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of two commercial methods for the susceptibility testing of Candida species: Vitek 2
    Siqueira RA; Doi AM; de Petrus Crossara PP; Koga PCM; Marques AG; Nunes FG; Pasternak J; Martino MDV
    Rev Iberoam Micol; 2018; 35(2):83-87. PubMed ID: 29580699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents.
    Alexander BD; Byrne TC; Smith KL; Hanson KE; Anstrom KJ; Perfect JR; Reller LB
    J Clin Microbiol; 2007 Mar; 45(3):698-706. PubMed ID: 17202279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.